Janus Henderson Group PLC Seres Therapeutics, Inc. Transaction History

Janus Henderson Group PLC

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$2.33 - $5.07 $7.59 Million - $16.5 Million	-3,259,399 Reduced 53.67%	2,813,543 $6.7 Million
Q2 2023 Aug 14, 2023	SELL	$4.67 - $6.55 $24.4 Million - $34.2 Million	-5,227,873 Reduced 46.26%	6,072,942 $29.1 Million
Q1 2023 May 15, 2023	BUY	$4.95 - $6.09 $259,988 - $319,865	52,523 Added 0.47%	11,300,815 $64.1 Million
Q4 2022 Feb 14, 2023	BUY	$5.09 - $9.05 $432,873 - $769,648	85,044 Added 0.76%	11,248,292 $63 Million
Q3 2022 Nov 14, 2022	BUY	$3.5 - $7.2 $20.3 Million - $41.7 Million	5,792,839 Added 107.87%	11,163,248 $71.7 Million

Q2 2022 Aug 15, 2022	SELL	$2.7 - $7.62 $1.18 Million - $3.32 Million	-436,271 Reduced 7.51%	5,370,409 $18.4 Million
Q1 2022 May 16, 2022	BUY	$6.3 - $8.84 $4.73 Million - $6.64 Million	751,581 Added 14.87%	5,806,680 $41.3 Million
Q4 2021 Feb 14, 2022	BUY	$6.02 - $11.43 $4.31 Million - $8.19 Million	716,298 Added 16.51%	5,055,099 $42.1 Million
Q3 2021 Nov 16, 2021	BUY	$5.46 - $22.6 $2.91 Million - $12 Million	533,062 Added 14.01%	4,338,801 $30.2 Million
Q2 2021 Aug 16, 2021	BUY	$18.46 - $24.36 $2.91 Million - $3.84 Million	157,806 Added 4.33%	3,805,739 $90.8 Million
Q1 2021 May 17, 2021	BUY	$17.66 - $28.92 $17.7 Million - $29 Million	1,002,659 Added 37.9%	3,647,933 $75.1 Million
Q4 2020 Feb 16, 2021	BUY	$23.25 - $37.73 $17 Million - $27.6 Million	731,197 Added 38.2%	2,645,274 $64.8 Million
Q3 2020 Nov 16, 2020	BUY	$3.74 - $28.74 $7.16 Million - $55 Million	1,914,077 New	1,914,077 $54.2 Million

100

62.7M

36.9K

476K

Ticker MCRB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 124,072,000
Market Cap $89.3M
Description
Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the ...

Get notified when there are updates to the investment portfolio of Janus Henderson Group PLC, based on Form 13F filings with the SEC.

Stay updated on Janus Henderson Group PLC with notifications on news.